These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 15761193)

  • 41. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor.
    Jones SP; Gibson MF; Rimmer DM; Gibson TM; Sharp BR; Lefer DJ
    J Am Coll Cardiol; 2002 Sep; 40(6):1172-8. PubMed ID: 12354446
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High-dose rosuvastatin in chronic heart failure promotes vasculogenesis, corrects endothelial function, and improves cardiac remodeling--results from a randomized, double-blind, and placebo-controlled study.
    Erbs S; Beck EB; Linke A; Adams V; Gielen S; Kränkel N; Möbius-Winkler S; Höllriegel R; Thiele H; Hambrecht R; Schuler G
    Int J Cardiol; 2011 Jan; 146(1):56-63. PubMed ID: 20236716
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The endothelial-protective effects of HMG-CoA reductase inhibition in the setting of ischemia and reperfusion injury.
    Liuni A; Luca MC; Gori T; Parker JD
    Clin Hemorheol Microcirc; 2010; 45(2-4):161-7. PubMed ID: 20675896
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 3-HMG-Coenzyme A reductase inhibition and extracellular matrix gene expression in the pressure-overloaded rat heart.
    Cirrincione GM; Boluyt MO; Hwang HS; Bleske BE
    J Cardiovasc Pharmacol; 2006 Apr; 47(4):521-30. PubMed ID: 16680065
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Heart rate reduction induced by the if current inhibitor ivabradine improves diastolic function and attenuates cardiac tissue hypoxia.
    Fang Y; Debunne M; Vercauteren M; Brakenhielm E; Richard V; Lallemand F; Henry JP; Mulder P; Thuillez C
    J Cardiovasc Pharmacol; 2012 Mar; 59(3):260-7. PubMed ID: 22075752
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rosuvastatin but not ezetimibe improves endothelial function in patients with heart failure, by mechanisms independent of lipid lowering.
    Gounari P; Tousoulis D; Antoniades C; Kampoli AM; Stougiannos P; Papageorgiou N; Roulia G; Stefanadi E; Siasos G; Tsioufis C; Stefanadis C
    Int J Cardiol; 2010 Jun; 142(1):87-91. PubMed ID: 19200613
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rosuvastatin changes cytokine expressions in ischemic territory and preserves heart function after acute myocardial infarction in rats.
    Hu X; Sun A; Xie X; Huang Z; Jia J; Yao R; Ge J
    J Cardiovasc Pharmacol Ther; 2013 Mar; 18(2):162-76. PubMed ID: 23139358
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Soluble, platelet-bound, and total P-selectin as indices of platelet activation in congestive heart failure.
    Chung I; Choudhury A; Patel J; Lip GY
    Ann Med; 2009; 41(1):45-51. PubMed ID: 18618353
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High-dose atorvastatin improves hypercholesterolemic coronary endothelial dysfunction without improving the angiogenic response.
    Boodhwani M; Nakai Y; Voisine P; Feng J; Li J; Mieno S; Ramlawi B; Bianchi C; Laham R; Sellke FW
    Circulation; 2006 Jul; 114(1 Suppl):I402-8. PubMed ID: 16820608
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Beneficial effects of rosuvastatin on aortic adverse remodeling in nitric oxide-deficient rats.
    Neto-Ferreira R; Novaes Rocha V; da Silva Torres T; Mandarim-de-Lacerda CA; de Carvalho JJ
    Exp Toxicol Pathol; 2011 Jul; 63(5):473-8. PubMed ID: 20537513
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Protective effects of rosuvastatin in experimental renal failure rats via improved endothelial function.
    Liu YZ; Liu M; Zhang YM; Kang L; Chen PZ; Wang ZF; Feng Y; Zheng JH
    Biol Res Nurs; 2013 Jul; 15(3):356-64. PubMed ID: 22544519
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction.
    Fraccarollo D; Widder JD; Galuppo P; Thum T; Tsikas D; Hoffmann M; Ruetten H; Ertl G; Bauersachs J
    Circulation; 2008 Aug; 118(8):818-27. PubMed ID: 18678774
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Albumin activation of NAD(P)H oxidase activity is mediated via Rac1 in proximal tubule cells.
    Whaley-Connell AT; Morris EM; Rehmer N; Yaghoubian JC; Wei Y; Hayden MR; Habibi J; Stump CS; Sowers JR
    Am J Nephrol; 2007; 27(1):15-23. PubMed ID: 17204833
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2.
    Kilic U; Bassetti CL; Kilic E; Xing H; Wang Z; Hermann DM
    Neuroscience; 2005; 134(3):901-6. PubMed ID: 16009498
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The direct factor Xa inhibitor Rivaroxaban reduces platelet activation in congestive heart failure.
    Flierl U; Fraccarollo D; Micka J; Bauersachs J; Schäfer A
    Pharmacol Res; 2013 Aug; 74():49-55. PubMed ID: 23714416
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The nitric oxide donor pentaerythritol tetranitrate reduces platelet activation in congestive heart failure.
    Flierl U; Fraccarollo D; Widder JD; Micka J; Neuser J; Bauersachs J; Schäfer A
    PLoS One; 2015; 10(4):e0123621. PubMed ID: 25928879
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Statin treatment and 3' polyadenylation of eNOS mRNA.
    Kosmidou I; Moore JP; Weber M; Searles CD
    Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2642-9. PubMed ID: 17916773
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.
    Ho RH; Tirona RG; Leake BF; Glaeser H; Lee W; Lemke CJ; Wang Y; Kim RB
    Gastroenterology; 2006 May; 130(6):1793-806. PubMed ID: 16697742
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Activation of porcine endothelium in response to xenogeneic serum causes thrombosis independently of platelet activation.
    Galbusera M; Buelli S; Gastoldi S; Macconi D; Angioletti S; Testa C; Remuzzi G; Morigi M
    Xenotransplantation; 2005 Mar; 12(2):110-20. PubMed ID: 15693841
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation.
    Bousette N; Hu F; Ohlstein EH; Dhanak D; Douglas SA; Giaid A
    J Mol Cell Cardiol; 2006 Aug; 41(2):285-95. PubMed ID: 16797584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.